Changcheng Zhu

https://assets.montefioreeinstein.org/profiles/images/Zhu_Changcheng_MD_2x.jpg

First Name

Changcheng

Last Name

Zhu

NPI

1407936909

Faculty ID

10578

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Thoracic pathology, Head &amp; Neck Pathology, Gynecological Pathology and Lung Transplant Pathology<br /><quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Lung cancer<br />

Elsevier Profile

EMR ID

4827

Is Open Scheduling

Off

Kathleen D. Whitney

https://assets.montefioreeinstein.org/profiles/images/physphoto/Whitney_Kathleen_D_MD_3514.jpg

First Name

Kathleen

Last Name

Whitney

NPI

1821178328

Faculty ID

6789

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

3851

Is Open Scheduling

Off

Daniel A. Weiser

https://assets.montefioreeinstein.org/profiles/images/Weiser_Daniel_MD_2x.jpg

First Name

Daniel

Last Name

Weiser

NPI

1225239700

Faculty ID

13846

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><span style="text-decoration: underline;"><strong>Childhood cancer research laboratory</strong></span></p>
<p>Our laboratory is focused on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. In such patients with typically incurable cancer, we are striving to identify new approaches to and types of treatment. We have multiple ongoing projects:</p>
<p><strong>+ Identification of biologic drivers of ultra-high-risk neuroblastoma</strong>. Neuroblastoma is one of the most common and deadly childhood cancers. Despite intensive research, there are limited therapeutic strategies for patients with <em>de novo </em>chemotherapy resistance that leads to particularly poor outcomes. We have been studying neuroblastoma since 2009 and are identifying additional biologic drivers of highly lethal tumors.</p>
<p>We compare tumor features from patients with early death from tumor progression compared to those with a maintained complete response. We assess unique histo-morphologic and proteomic features and computationally integrate these data with genomic and transcriptomic datasets to develop a combined predictor of primary refractory disease. Patients with this entity require non-standard and/or intensified treatment. Oncogenic drivers are being characterized in the lab which will facilitate strategies for novel pharmacologic intervention.</p>
<p><strong>+ Characterization of neuroblastoma development from neural crest cells</strong>.&nbsp; We are studying pathways and interactions that results in uncontrolled cell proliferation early in neuroblastoma development with an ultimate goal of identifying new targets and approaches for pharmacologic intervention.</p>
<p><strong>+ Evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma</strong>.&nbsp; With expected outcomes lagging behind those of more common childhood cancers, children with neuroblastoma require new approaches to treatment. Our lab works with multiple international clinical and research consortium groups to perform preclinical studies that substantiate human clinical trials.&nbsp;</p>
<p><strong>+ Detection of circulating tumor DNA in osteosarcoma</strong>. With no reliable non-invasive approach for disease monitoring during and after treatment, we are applying cutting edge next-generation sequencing approaches to identify solid tumors with a blood-based &ldquo;liquid&rdquo; biopsies. This will allow clinicians to assess tumor responsiveness to chemotherapy and predict likelihood of recurrence.</p>
<p><strong>+ Assessment of accelerated aging using miRNA-seq in survivors of childhood cancer</strong>. Chemotherapy has many untoward effects on healthy cells and leads to many signs of accelerated aging in children treated for cancer. Using a known microRNA &ldquo;aging&rdquo; signature discovered at Albert Einstein College of Medicine, we are studying what causes this phenotype in childhood cancer, with a goal of offering improved intervention to minimize long-term toxicity of treatment.</p>
<p><strong><span style="text-decoration: underline;">Physician Summary</span></strong></p>
<p>Daniel A. Weiser, MD, is board-certified in pediatric hematology/oncology with clinical expertise in neuroblastoma and other tumors of the adrenal glands, kidneys, liver, and gonads. He is the medical director of the intra-abdominal solid tumor program at the Children&rsquo;s Hospital at Montefiore and brings together a highly specialized multi-disciplinary care team to provide comprehensive treatment for diverse pediatric malignancies. In addition, Dr. Weiser directs a childhood cancer research laboratory that focuses on the identification of new targeted agents for cancer therapy, especially in the treatment of rare and aggressive malignancies such as neuroblastoma. His research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise for improving management of all patients with solid tumors.</p>
<p>Dr. Weiser participates in the efforts of a number of professional organizations including the Children&rsquo;s Oncology Group (COG), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), Advances in Neuroblastoma Research Association (ANRA), National Pediatric Cancer Foundation (NPCF), and the American Academy of Pediatrics (AAP). He has received numerous awards including the Brigid Leventhal Special Merit Award from ASCO and the Conquer Cancer Foundation, and a prestigious K12 from the National Cancer Institute for the training of the next generation of physician-scientists in pediatric cancer. Dr. Weiser is actively involved in teaching and mentorship of trainees, and takes great pride in providing advanced and compassionate care to his patients and their families.</p>
<p><strong>Clinical Expertise</strong></p>
<ul>
<li>Neuroblastoma (adrenal tumors)</li>
<li>Wilms tumor (renal tumors)</li>
<li>Hepatoblastoma (liver tumors)</li>
<li>Germ cell tumors (including testicular and ovarian tumors)</li>
<li>Thyroid and other rare tumors</li>
<li>Experimental therapeutics</li>
<li>Cancer genetics and biomarkers</li>
</ul>
<p><strong>Board Certifications</strong></p>
<ul>
<li>Pediatrics</li>
<li>Pediatric Hematology/Oncology</li>
</ul>
<p><strong>Professional Education</strong></p>
<ul>
<li>M.D. &ndash; Stony Brook University, NY</li>
<li>Residency &ndash; Children&rsquo;s Hospital of NY-Presbyterian, Columbia University, NY</li>
<li>Chief Residency &ndash; Children&rsquo;s Hospital of NY-Presbyterian, Columbia University, NY</li>
<li>Fellowship &ndash; The Children&rsquo;s Hospital of Philadelphia, PA</li>
</ul>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Clinical Focus

DR. Weiser's clinical focuses are neuroblastoma and adrenal tumors, Wilms tumor and other kidney (renal) tumors, hepatoblastoma, and other liver tumors, germ cell tumors (including testicular and ovarian tumors), Thyroid and other rare tumors, experimental therapeutics, and cancer genetics and biomarkers.&nbsp;

Research Focus

Dr. Weiser&rsquo;s research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise in the treatment of all solid tumors. Dr. Weiser&rsquo;s laboratory focuses on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. He has multiple ongoing projects, such as identification of biologic drivers of neuroblastoma at ultra-high risk for treatment failure, characterization of neuroblastoma development from neural crest cells, and evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma, among others.

Elsevier Profile

EMR ID

5755

Biography

<p>Daniel A. Weiser, MD, is a Medical Director of the Intra-abdominal Solid Tumor Program in the Pediatrics Hematology/Oncology department at Children&rsquo;s Hospital at Montefiore. He is also Associate Professor in the Pediatrics and Genetics departments at the Albert Einstein College of Medicine. His clinical focuses are neuroblastoma and adrenal tumors, Wilms tumor and other kidney (renal) tumors, hepatoblastoma and other liver tumors, germ cell tumors (including testicular and ovarian tumors), Thyroid and other rare tumors, experimental therapeutics, and cancer genetics and biomarkers. Dr. Weiser is actively involved in teaching and mentorship of trainees and takes great pride in his active participation in patient care.</p><p>Dr. Weiser received his Bachelor of Science in Neurobiology in 1995 at Haverford College, PA. In 2004, he received his Doctor of Medicine at Stony Brook University School of Medicine, NY. He is currently earning his Master of Science in Translational Research at the University of Pennsylvania. He began a residency in Pediatrics at the New York-Presbyterian, Columbia University in 2007. Dr. Weiser then completed a three-year fellowship in Pediatric Hematology/Oncology at The Children&rsquo;s Hospital of Philadelphia. </p><p>Dr. Weiser&rsquo;s research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise in the treatment of all solid tumors. Dr. Weiser&rsquo;s laboratory focuses on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. He has multiple ongoing projects, such as identification of biologic drivers of neuroblastoma at ultra-high risk for treatment failure, characterization of neuroblastoma development from neural crest cells, and evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma, among others. His research has been published in many reviewed journals. </p><p>Dr. Weiser participates in the efforts of a number of professional organizations including the Children&rsquo;s Oncology Group (COG), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), and the American Academy of Pediatrics (AAP). He has received many awards including the Brigid Leventhal Special Merit Award through ASCO, and he has been awarded a prestigious K12 from the NCI for the training of the next generation of physician-scientists in pediatric cancer.</p><p>He is board certified in Pediatric Hematology/Oncology and General Pediatrics.</p>

Is Open Scheduling

Off

Esperanza Villanueva-Siles

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/83dd1f30-84f7-11ef-b387-d348df9d586b.jpg

First Name

Esperanza

Last Name

Villanueva-Siles

NPI

1518047018

Faculty ID

10058

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

4730

Is Open Scheduling

Off

Aaron Zev Tokayer

https://assets.montefioreeinstein.org/profiles/images/Tokayer_Aaron_MD_420x504.jpg

First Name

Aaron

Last Name

Tokayer

NPI

1336220755

Faculty ID

704

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Tokayer received his B.A. in from Yeshiva College and his M.D. from Albert Einstein College of Medicine of Yeshiva University. &nbsp;He completed an internship and residency at the Bronx Municipal Hospital Center and GI and Hepatology fellowship at Johns Hopkins Medical Center. He received an MHS degree in Clinical Epidemiology from Johns Hopkins School of Public Health. Dr. Tokayer then joined the Montefiore GI Faculty in 1992. He has been involved in the spectrum of clinical patient care, endoscopic interventions and teaching in the GI fellowship program. His areas of interest include clinical practice, patient care and education, endoscopic procedures and interventions, functional GI and motility disorders. He is Director of the GI Motility Lab where studies such as Esophageal Manometry,&nbsp; Esophageal Acid Monitoring and Impedance Testing, Ano-rectal Manometry and Defecatory Testing, Hydrogen Breath Testing for Bacterial overgrowth and Carbohydrate Maldigestion , and studies of gastric and intestinal transit. He works closely with colleagues of the Department of Radiology and Nuclear Medicine as well as the Department of Surgery in diagnosing and treating GI motility disorders.</p>

Research Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Is Open Scheduling

Off

Asli S. Sucu

https://assets.montefioreeinstein.org/profiles/images/16076-asli-sucu.jpg

First Name

Asli

Last Name

Sucu

NPI

1477815934

Faculty ID

16076

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

55869

Is Open Scheduling

Off

Jonathan M. Schwartz

https://assets.montefioreeinstein.org/profiles/images/Schwartz_Jonathan_MD_2x.jpg

First Name

Jonathan

Last Name

Schwartz

NPI

1215945738

Faculty ID

648

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Jonathan M. Schwartz is a board Certified Transplant Hepatologist. &nbsp;He is a graduate of Tel Aviv University, Sackler School of Medicine. He was an Internal Medicine Resident at Albert Einstein College of Medicine and a Fellow in Gastroenterology/Transplant Hepatology at the University of Washington in Seattle. &nbsp;He returned to New York in 2011 from Portland, Oregon where he served as an Associate Professor of Medicine at Oregon Health and Sciences University.</p>
<p>Dr. &nbsp;Schwartz has an interest in treating patients with acute and chronic liver diseases including those patients with advanced liver diseases who require liver transplantation.</p>
<p>He has a special interest in the multidisciplinary care of patients with liver tumors.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p><strong><br /></strong></p>
<ul>
<li>Estes JD, Stolpman D, Olyaei A, Ham JM, <strong>Schwartz JM</strong>, Orloff SL.&nbsp; High Prevalence of Potentially Hepatotoxic Herbal Supplement Use in Fulminant Hepatic Failure Patients. Arch Surg. 2003;138(8):852-8.</li>
<li><strong>Schwartz JM</strong>, Beymer C, Althaus SJ, Larson AM, Zaman A, Glickerman D, Kowdley KV.&nbsp; Cardiopulmonary Consequences of Transjugular Intrahepatic Portosystemic Shunts: Role of Increased Pulmonary Artery Pressure. J Clin Gastroenterol 2004;38(7):590-594.</li>
<li>Lim LL, Scarborough J, Thorne J, Graham E, Kempen J, Mackensen F, Nguyen Q D, Prabriputaloong T, Read R, Suhler EB, <strong>Schwartz JM</strong>, &nbsp;Smith JR. Uveitis in Patients with Autoimmune Hepatitis. Am J Ophthalmol. 2009;147(2):332-338.</li>
<li>O&rsquo;Glasser AY, Scott DA, Corless CL, Zaman A, Sasaki A, Gopal DV, Rayhill SC, Orloff SL, Ham JM, Rabkin JM, Flora K, Davies CH, Broberg CS, and <strong>Schwartz JM.</strong>Hepatic and Cardiac Iron Overload Among Patients with End-Stage Liver Disease Referred for Liver Transplantation. Clinical Transplantation. Clin Transplant. 2010 Sep-Oct;24(5):643-51.</li>
<li>Kanwal F, Befeler A, Chari R, Marrero J, Kahn J, Afdhal N, Morgan T, Roberts L, Mohanty SR, <strong>Schwartz J</strong>, Van Thiel D, Hassanein TI, Li J, Zeringue A, DiBisceglie A. Rate of Potentially Curative Treatment in Patients with Hepatocellular Carcinoma.&nbsp; Aliment Pharmacol Ther. 2012 Aug;36(3):257-65.</li>
<li>Bichoupan K1,&nbsp;<strong>Schwartz JM,</strong>&nbsp;Martel-Laferriere V,&nbsp;Giannattasio ER,&nbsp;Marfo K,&nbsp;Odin JA,&nbsp;Liu LU,&nbsp;Schiano TD,&nbsp;Perumalswami P,&nbsp;Bansal M,&nbsp;Gaglio PJ,&nbsp;Kalia H,Dieterich DT,&nbsp;Branch AD,&nbsp;Reinus JF. Effect of Fibrosis on Adverse Events in Patients with Hepatitis C Treated with Telaprevir. Aliment Pharmacol Ther.&nbsp;2014;39(2):209-16.</li>
<li><strong>Schwartz J</strong> and Carithers RL.&nbsp; Epidemiology and Etiologic Associations of Primary Hepatocellular Carcinoma.&nbsp; In Rose BD, editor. Up to date in Gastroenterology and Hepatology.&nbsp; Up to date, Inc. Wellesley, MA, Updated 2014.</li>
<li><strong>Schwartz JM </strong>and Carithers RL, Jr.&nbsp; Clinical features, diagnosis, and screening for primary hepatocellular carcinoma.&nbsp; Up to date in Gastroenterology and Hepatology.&nbsp; Up to date, Inc. Wellesley, MA, Updated 2014.</li>
<li>Curley SA, Stewart KE, <strong>Schwartz JM</strong>, Carthers RL, Jr.&nbsp; Nonsurgical therapies for localized hepatocellular carcinoma.&nbsp; Up to date, Inc. Wellesley, MA, Updated 2014.<strong>&nbsp;</strong></li>
<li><strong>Schwartz JM</strong>.&nbsp; Approach to the patient with a focal liver lesion.&nbsp; Up to date Inc Gastroenterology and Hepatology.&nbsp; Up to date, Inc. Wellesley, MA, Updated 2014.</li>
<li>Hartwell L and <strong>Schwartz JM.&nbsp; </strong>AsymptomaticLiver Chemistry Abnormalities. Journal of Clinical Outcomes Management. 2009; 16 (11): 525-34.</li>
<li>Urquhart J<strong>, Schwartz, JM.</strong> Hepatocellular Carcinoma Surveillance in a Western Population with Hepatitis B. Current Hepatitis Reports, 2011.</li>
<li><strong>Schwartz, JM </strong>and Reinus JF.&nbsp; Prevalence and Natural History of Alcoholic Liver Disease.&nbsp; Clinics in Liver Disease. 2012; 16 (4): 659-66.</li>
</ul>
<p>&nbsp;</p>

EMR ID

3842

Is Open Scheduling

Off

Garrison Pease

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/b3b813e0-c4a7-11eb-925b-439657343c68.jpg

First Name

Garrison

Last Name

Pease

NPI

1598104721

Faculty ID

16562

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Genitourinary/Urologic (prostate, kidney, bladder, testicle, penis, adrenal gland) Pathology, with focus on one-on-one teaching at the scope with residents and medical students, along with quality assurance and quality improvement mind-set with emphasis on lab efficiency and patient-centered turn-around time.<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Genitourinary/Urologic Pathology, Quality Assurance and Improvement<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

EMR ID

113941

Biography

<p>Garrison Pease, MD, is an attending surgical pathologist and Assistant Professor, Pathology at Montefiore Einstein. His clinical focus centers on genitourinary and urologic pathology, with a focus on one-on-one teaching at the scope with residents and medical students. He is also focused on quality assurance and quality improvement with an emphasis on lab efficiency and patient-centered turn-around time.</p><p>After obtaining his Bachelor of Arts in biology from Saint John's University (Collegeville, MN) in 2009, Dr. Pease earned his Doctor of Medicine at the University of Minnesota in 2013. He completed his anatomic and clinical pathology residency at the University of University of Chicago - NorthShore in 2017, where he was Chief Resident in his final two years. Following this, Dr. Pease completed a general surgical pathology fellowship at Washington University &ndash; St. Louis in 2018, followed by a genitourinary pathology fellowship at the University of Washington in 2019.</p><p>Dr. Pease&rsquo;s research is focused on genitourinary and urologic pathology and quality assurance and improvement. He has worked on the College of American Pathologists (CAP) self and peer-based laboratory inspections. His work has been published in several peer-reviewed journals and shared through abstracts and poster presentations nationally and internationally.</p><p>Dr. Pease is a Diplomate of the American Board of Pathology and is board certified in Anatomic and Clinical Pathology. He is a member of the United States and Canadian Academy of Pathology and the College of American Pathologists. In 2021, Dr. Pease won the Department of Pathology Outstanding Teaching Award from Montefiore Einstein's Pathology Residency program.</p>

Is Open Scheduling

Off

Jennifer M. Oliver-Krasinski

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/11db4220-42b1-11ed-ad3f-b1cabe5c6255.jpg

First Name

Jennifer

Last Name

Oliver-Krasinski

NPI

1275859209

Faculty ID

15576

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

1863

Is Open Scheduling

Off

Deepa G. Manwani

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/ef575e50-ee0d-11ee-904c-09056fc0ef1f.jpg

First Name

Deepa

Last Name

Manwani

NPI

1922077544

Faculty ID

11847

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Languages

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Manwani is a pediatric hematologist who leads the sickle cell team at CHAM. The team offers treatment and support for young children and teens with sickle cell disease and their families, including weekly support groups and an annual Sickle Cell Awareness Day event focused on new research and strategies for living with this disease.</p>

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Clinical Focus

<p>Benign hematology, anemia, sickle cell disease, thalassemia, hemophilia, bleeding disorders, thrombosis, neutropenia, thrombocytopenia, ITP, erythrocytosis, thrombocytosis, leukocytosis.</p>

Research Focus

<p>Sickle Cell Disease: Novel therapies, Role of adhesion and neutrophils, Alloimmunization, Transition to adult care, Fetal hemoglobin induction, Gut Microbiome, Pain, Chronic Pain, Quality Improvement.</p>

Elsevier Profile

EMR ID

5141

Biography

<p>Deepa Manwani, MD, is Director, Pediatric Hematology at Children?s Hospital at Montefiore, as well as a Professor in the Department of Pediatrics at Albert Einstein College of Medicine. Dr. Manwani?s clinical focus is on benign hematology, anemia, sickle cell disease, thalassemia, hemophilia, bleeding disorders, thrombosis, neutropenia, thrombocytopenia, ITP, erythrocytosis and leukocytosis. </p><p>Dr. Manwani graduated from B.J. Medical College, Poona University, India, in 1991, earning her Doctor of Medicine. She became a Research Assistant at the Children?s Hospital Oakland in 1991 before beginning an internship in Pediatrics at NSUH-Cornell University Med Center in 1993. Following her internship, Dr. Manwani completed a residency in Pediatrics at the same institution. In 1996, she began a fellowship in Pediatrics Hematology/Oncology at Mount Sinai School of Medicine in New York. </p><p>Dr. Manwani?s research focuses on fetal hemoglobin activating agents, adhesive cellular interactions in vaso-occlusion in sickle cell disease (SCD) and contribution of neutrophils to SCD pathophysiology. She completed the R01 funded Phase 1 study of IVIG in the treatment of SCD vaso-occlusive crises and is currently leading the R01 funded Phase II study. Dr. Manwani is currently participating in studies aimed at increased adherence to hydroxyurea and improved transition to adult care. She is also collaborating with investigators at Case Western Reserve University on an NHLBI R01 funded study to standardize monitoring of cellular adhesion in SCD patients using a novel microfluidic assay. Her contributions have been recognized by the Sickle Cell Thalassemia Patient Network of New York in the form of the Distinguished Service Award in March 2015. Dr. Manwani?s studies have been published nationally in various reviewed journals and books. </p><p>Dr. Manwani has received many awards, including Castle Connolly Top Doctor in 2016, New York Magazine Best Doctor and New York Metro Area?s Top Doctors in 2017. </p>

Is Open Scheduling

Off